Working… Menu

A Study of Pembrolizumab in Patients With Neuroendocrine Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02939651
Recruitment Status : Active, not recruiting
First Posted : October 20, 2016
Last Update Posted : September 27, 2019
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Fox Chase Cancer Center

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Actual Primary Completion Date : September 2, 2018
Estimated Study Completion Date : January 2020